Beilu Pharmaceutical Wins Emerging Pharmaceutical Internationalization Award at CPHI China

CPHI & PMEC China 2025 recently made a grand debut in Shanghai. This year's exhibition showcases the latest innovations and cutting-edge technologies across the entire pharmaceutical supply chain, with an unprecedented lineup of global participants. Beilu Pharmaceutical, a company with decades of deep expertise and continuous innovation in the pharmaceutical sector, actively participated in the event. By sharing the stage with top-tier global pharmaceutical enterprises, Beilu not only demonstrated its robust capabilities but also forged new connections with international partners, expanding its footprint and integration within the global pharmaceutical supply chain. We warmly welcome partners, industry professionals, and stakeholders to visit our booth for in-depth discussions and collaboration opportunities.

During the exhibition, CPHI & PMEC China once again hosted the prestigious CPHI Celebration Awards, adhering to an industry-driven mindset and a global perspective. The awards are judged based on rigorous professional criteria combined with industry voting, aiming to highlight their authoritative value, recognize innovation benchmarks, and empower the high-quality development of the pharmaceutical sector.

As a leading platform for global pharmaceutical exchange and collaboration, the CPHI China Annual Awards Ceremony brought together nearly 500 key decision-makers, innovators, and changemakers from the pharmaceutical industry, including over 250 international buyers, to witness the recognition of excellence among Chinese pharmaceutical enterprises.

At this year's ceremony, Beilu Pharmaceutical distinguished itself from hundreds of nominated companies, earning the "Emerging Pharmaceutical Internationalization Awards" for its outstanding global strategic vision and strong industry capabilities. This accolade reflects the international market's high recognition of Beilu's comprehensive strength and highlights the growing momentum of Chinese pharmaceutical companies as they step confidently onto the global stage.

Beilu Pharmaceutical's recent award signifies authoritative recognition from the international market for the company's global strategic deployment. In recent years, Beilu has achieved notable results in its early-stage international market expansion. The company's exported products—primarily contrast agent formulations and active pharmaceutical ingredients (APIs)—are now distributed across markets in South America, Africa, and Asia.

In 2024, Beilu successfully launched its entire line of contrast agents overseas, resulting in a significant increase in revenue. On the API front, HICHI Pharmaceutical continues to expand the international reach of its iodine-based APIs, while the Cangzhou branch, which produces gadolinium-based APIs, is also steadily moving toward internationalization. With the completion of EU GMP certification and Brazil ANVISA GMP compliance certification, the pace of global expansion for the company's contrast agent products is expected to accelerate further.

Currently, Beilu's Iohexol Injection has been granted registration approvals in the Netherlands, Hungary, and other EU countries, laying a solid foundation for expanding its presence in the European market. Meanwhile, registration of its Jiuwei Zhenxin Granules in Hong Kong and Thailand is progressing as planned, paving the way for future exports to Southeast Asia and beyond.

Looking ahead, Beilu Pharmaceutical will continue to pursue a dual-market strategy, advancing both domestic and international development. Beilu is committed to deepening its global footprint and working hand-in-hand with international partners to write a new chapter in the global journey of Chinese pharmaceuticals.